🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07514039
Enrolling by invitation Not applicable

Photolithography Microstructure Myopia Management Lenses in Preventing and Controlling Myopia in Children and Adolescents

NCT07514039 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Eye Disease Prevention and Treatment Center
Phase
Not applicable
Started
2026-02-01
Last updated
2026-04-07

Condition(s) studied

Myopia, Child Myopia Progression

Investigational drug(s) / intervention(s)

Myopia management lens

Myopia management lens: Microstructure myopia management lens

Study summary

Evaluate the effectiveness of different lithographic microstructured myopia management lenses in controlling the progression of myopia in children and adolescents, as well as the safety and comfort of wearing them. Explore effective defocus microlens designs for myopia control and the feasibility of applying lithographic microstructured myopia management lenses in myopia prevention and control.

Eligibility

Sex
ALL
Min age
6 Years
Max age
14 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age: 6 to 14 years old. * After administering 1% Cyclopentolate Hydrochloride Eye Drops (Saifeijie) to induce ciliary muscle paralysis, both eyes showed refractive errors between -0.50D and -4.00D, with binocular lens differences ≤ 1.50D and anisometropia ≤ 1.50D. Best corrected visual acuity was 5.0 or better. * Have not used over-focus glasses, corneal reshaping lenses, defocus flexible glasses, progressive lenses, atropine eye drops, red light therapy, acupuncture, moxibustion, or other myopia prevention methods within the past three months. * The subject is willing to receive treatment, and their legal guardian has signed an informed consent form. Exclusion Criteria: * Diagnosed with persistent strabismus. * Diagnosed with pathological myopia. * Other congenital eye diseases. * Other reasons the research doctor deems unsuitable for inclusion in the project.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shanghai Eye Diseases Prevention &Treatment Center/ Shanghai Eye Hospital, School of Medicine, Tongji University Shanghai China

More Shanghai Eye Disease Prevention and Treatment Center trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07514039 on ClinicalTrials.gov ↗ ← All trials in China